Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

2069

Figures (1-3)

231

Tables (1-2)

229

Sum=2582

Publishing Process of This Article

Item

Count

Browse

Download

501

Sum=555

Mar 26, 2024 (publication date) through Feb 2, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Cases. Mar 26, 2024; 12(9): 1585-1596
Published online Mar 26, 2024. doi: 10.12998/wjcc.v12.i9.1585

Table 1 Patient characteristics

		Frequency	%
Age, yr	1	1	25.0
	4	1	25.0
	9	2	50.0
Sex	Female	1	25.0
Sex	Male	3	75.0
Etiology of cerebral palsy	Hypoxia during birth	2	50.0
	Hypoxia with bleeding in the surgical field after tonsillectomy operation	1	25.0
	Cardiac arrest	1	25.0
Comorbidity	None	4	100.0
Cerebral palsy duration and first transplantation	1 year	1	25.0
	13 months	1	25.0
	7 years	1	25.0
	9 years	1	25.0

Citation: Boyalı O, Kabatas S, Civelek E, Ozdemir O, Bahar-Ozdemir Y, Kaplan N, Savrunlu EC, Karaöz E. Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy. World J Clin Cases 2024; 12(9): 1585-1596
URL: https://www.wjgnet.com/2307-8960/full/v12/i9/1585.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i9.1585